Why Lifecore Biomedical, Inc.’s (LFCR) Stock Is Up 5.29%
As of Friday, September 04, Lifecore Biomedical, Inc.’s LFCR share price has surged by 5.29%, which has investors questioning if this is right time to sell.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Michael Rose
Michael Rose
Michael Rose
Cynthia McLaughlin
| Share Statistics | LFCR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $164.7 | $3,749.2 | 25% |
|
| Shares Out (Mil) | 37.6 | 98.2 | 41% |
|
| Institutional Ownership | 89.7% | 89.6% | 57% |
|
| Float (Mil) | 19.3 | 70.7 | 28% |
|
| Beta | 1.09 | 1.19 | 65% |
|
| Avg Daily Volume (000s) | 117 | 590 | 38% |
|
| Price Change (52-week) |
(43.6%) | 87.5% | 17% |
|
| Growth | LFCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.1% | 7.8% | 37% |
|
| Net Income (5yr) | 11.0% | (11.2%) | 57% |
|
| EPS (5yr) | 13.3% | 2.5% | 53 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 76.2% | (15.0%) | 97% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 2 | na | |
| Current EPS | na | ($0.875) | na | |
| Month Ago EPS | na | ($0.890) | na | |
| # Rev Up | na | 0 | na | |
| # Rev Down | na | 0 | na | |
| Three Months Ago EPS | na | ($0.810) | na | |
| Year/Year Chg | na | 62.0% | 44.4% | |
| Financials | LFCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $130 | $810 | 28% |
|
| Net Income (TTM) (Mil) | ($31) | ($31) | 20% |
|
| EPS (TTM) | ($0.923) | ($0.300) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | $13 | $56 | 39% |
|
| Net Cash Flow (TTM) (Mil) | $3 | $3 | 50% |
|
| Long-Term Debt (Q1) (Mil) | $155 | $264 | 48% |
|
| Enterprise Value (Q1) (Mil) | $361 | $3,795 | 31% |
|
| Valuation | LFCR | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 3.81 | na |
|
| P/E | na | 39.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.8 | na |
|
| Ratios | LFCR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 31.4% | 47.6% | 37% |
|
| Net Margin | (23.8%) | (2.6%) | 16% |
|
| ROA | (13.1%) | (4.0%) | 23% |
|
| ROE | 188.0% | (7.7%) | 98% |
|
| Liabilities to Assets | 93.0% | 41.1% | 90% |
|
| F-Score | 3 | 5 | 18% |
|
Lifecore Biomedical, Inc. did not pass any screens on 9/3/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors